Kroger

Kroger reported Q2 operational gains from cost savings, profitable e-commerce growth and improved on-shelf availability, but identical sales were hit by a Cyclospora outbreak and pharmacy pressures. Management lowered full-year identical sales guidance to 0.2%–0.8% and expects a ~150 basis-point pharmacy headwind in Q4 due to new high-cost drugs, while saying profit won’t be affected. The company is prioritizing a multi-year customer value plan, expanding private-label penetration, resuming share repurchases and aiming to close the Giant Eagle acquisition in 2027 pending regulatory review. » More on finance.yahoo.com

Kroger reported adjusted EPS of $1.09 for Q2 (consensus $1.06) on revenue of $34.6bn, slightly below estimates. Same-store sales growth excluding fuel was only 0.2%, and management cut the full-year forecast for that metric to 0.2–0.8% (previously 1–2%). Higher gross margins, e-commerce and retail-media growth, and cost savings supported profitability, but investors were unsettled by weak demand and revision-related uncertainty; the stock fell about 1.95% in premarket trading. » More on de.investing.com

Harbor Mid Cap Value Fund named Kroger a top detractor in Q2 2026 after the grocery chain’s shares dropped more than 20% amid slowing same-store sales and inflationary pressure. Increased competition from lower-cost providers has forced Kroger to cut prices to defend market share. The stock is down about 15% year‑over‑year and closed at $58.59 on September 4, 2026, with a market cap near $35.9 billion. » More on finance.yahoo.com